Britain and America have signed a significant bilateral deal that will guarantee zero duties on British drug shipments going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on drugs through the public health system. This move ensures that tariffs on these vital exports will be held at zero for a duration of 36 months.
This agreement is in response to previous statements to dramatically increase duties on branded drug products, with potential rates mentioned up to one hundred percent.
"This deal with the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," an announcement said.
Trade Significance
Medicines represent one of the Britain's most significant exports to the United States, which is easily the primary market for major British pharmaceutical firms.
Export figures show that in the one-year period to the end of September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for a significant portion of British export trade in that period.
"This agreement secures work, increases investment and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Detailed UK Commitments
The deal entails several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, repayments were more than 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were heightened by claims that US consumers were paying several times more for the same drugs than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
